Simplify Your Life: Manage Your ALUNBRIG / Brigatinib Order Online

Lung cancer is one of the most common cancers in men and women, and is the leading cause of cancer-related mortality in the United States.1 According to the American Cancer Society, more than 155,000 Americans will die from lung cancer in 2017, representing approximately 25% of all cancer deaths.1 Non–small-cell lung cancer (NSCLC), the most common form of the disease, accounts for 80% to 85% of all lung cancer cases.2

As knowledge of lung cancer tumor cell biology has evolved, small-molecule drugs that target specific genetic mutations offer oncologists the opportunity to treat patients with NSCLC in a personalized fashion.3 Multiple driver oncogenes have been identified in lung cancer, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and KRAS.

Among US patients with advanced NSCLC, approximately 10% have EGFR mutations,3 approximately 23% have KRAS mutations,4 and up to 13% have ALK mutations.5 By identifying these mutations, oncologists can determine which patients can benefit from available targeted therapies.

Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC).

The drug was originally discovered by Ariad Pharmaceuticals, which was acquired by Takeda Pharmaceutical Company in February 2017.

Ariad Pharmaceuticals submitted the new drug application (NDA) for Alunbrig to the US Food and Drug Administration (FDA) in August 2016. It was accepted for review in October and the company was granted breakthrough therapy designation. Takeda received accelerated approval in April 2017.

The marketing authorisation application (MAA) for Alunbrig was submitted to the European Medicines Agency (EMA) in February 2017.

Non-small cell lung cancer causes

One of the most common forms of lung cancer, NSCLC occurs when lung cells become abnormal and begin to develop beyond control. In advanced stages, the disease spreads tumours to the brain, bones, adrenal glands, liver, and kidneys.

Smoking is considered to be the major risk factor associated with NSCLC. Symptoms include coughing, chest pain, coughing blood, loss of appetite, shortness of breath, and wheezing.

NSCLC accounts for approximately 85% of the estimated 222,500 new cases of lung cancer diagnosed per year in the US, according to the American Cancer Society’s estimates.

Alunbrig’s mechanism of action

Lung problems. ALUNBRIG may cause severe or life-threatening swelling (inflammation) of the lungs any time during treatment and can lead to death. These lung problems happen especially within the first week of treatment with ALUNBRIG. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening symptoms, including:

trouble breathing or shortness of breath

chest pain

cough with or without mucus

fever

High blood pressure (hypertension). ALUNBRIG may cause high blood pressure. Your healthcare provider will check your blood pressure before starting and during treatment with ALUNBRIG. Tell your healthcare provider right away if you get headaches, dizziness, blurred vision, chest pain or shortness of breath.

Slow heart rate (bradycardia). ALUNBRIG may cause very slow heartbeats that can be severe. Your healthcare provider will check your heart rate during treatment with ALUNBRIG. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint during treatment with ALUNBRIG. Tell your healthcare provider if you take any heart or blood pressure medicines.

Vision problems. ALUNBRIG may cause vision problems. Your healthcare provider may stop ALUNBRIG and refer you to an eye specialist if you develop severe vision problems during treatment with ALUNBRIG. Tell your healthcare provider right away if you have any loss of vision or any change in vision, including:

double vision

seeing flashes of light

blurry vision

light hurting your eyes

Top News from the IASLC 19th World Conference on Lung Cancer 2018 #WCLC2018

All The Most Important News and Updates form the International Association for the Study of Lung Cancer 19th World Conference – IASLC WCLC 2018 Roche’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer

September 24, 2018

Roche has announced results for its investigational medicine entrectinib, from an integrated…

Top Pharma News of the Week – September 24th

All The Most Important Pharmaceutical News Stories Of The Week – September 2018 – Week # 4 FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis

September 20, 2018

ACADIA Pharmaceuticals Inc. has announced that the FDA has completed a postmarketing review and…